资源 » 参考数据库 » 客户发表文献

至今，GenScript的服务及产品已被Cell, Nature, Science, PNAS等1300多家生物医药类杂志引用近万次，处于行业领先水平。NIH、哈佛、耶鲁、斯坦福、普林斯顿、杜克大学等约400家全球著名机构使用GenScript的基因合成、多肽服务、抗体服务和蛋白服务等成功地发表科研成果，再次证明GenScript 有能力帮助业内科学家Make research easy.

Sterile protection against human malaria by chemoattenuated PfSPZ vaccine.

Nature. 2017;

MordmüllerBenjamin，SuratGüzin，LaglerHeimo，ChakravartySumana，IshizukaAndrew S，LalremruataAlbert，GmeinerMarkus，CampoJoseph J，EsenMeral，RubenAdam J，HeldJana，CalleCarlos Lamsfus，MengueJuliana B，GebruTamirat，IbáñezJavier，SulyokMihály，JamesEric R，BillingsleyPeter F，NatashaK C，ManojAnita，MurshedkarTooba，GunasekeraAnusha，EappenAbraham G，LiTao，StaffordRichard E，LiMinglin，FelgnerPhil L，SederRobert A，RichieThomas L，SimB Kim Lee，HoffmanStephen L，KremsnerPet

Products/Services Used	Details	Operation
Recombinant Proteins	PfSPZ outside the hepatocytes were stained with an anti-PfCSP mAb (2A10, 6.86 μ g ml−1) (Protein Potential LLC, with permission from New York University School of Medicine) conjugated with Alexa Fluor 633 (far-red) (1 μ g ml−1; custom-conjugated at GenScript). The hepatocytes were then permeabilized with 0.1% Triton X-100 for 10 min at room temperature, and the PfSPZ inside the hepatocytes were stained with the anti-PfCSP mAb (2A10, 6.86 μ g ml−1) conjugated with Alexa Fluor 488 (green; 1 μ g ml−1, conjugated from Genscript).	Get A Quote

摘要

A highly protective malaria vaccine would greatly facilitate the prevention and elimination of malaria and containment of drug-resistant parasites. A high level (more than 90%) of protection against malaria in humans has previously been achieved only by immunization with radiation-attenuated Plasmodium falciparum (Pf) sporozoites (PfSPZ) inoculated by mosquitoes; by intravenous injection of aseptic， purified， radiation-attenuated， cryopreserved PfSPZ ('PfSPZ Vaccine'); or by infectious PfSPZ inoculated by mosquitoes to volunteers taking chloroquine or mefloquine (chemoprophylaxis with sporozoites). We assessed immunization by direct venous inoculation of aseptic， purified， cryopreserved， non-irradiated PfSPZ ('PfSPZ Challenge') to malaria-naive， healthy adult volunteers taking chloroquine for antimalarial chemoprophylaxis (vaccine approach denoted as PfSPZ-CVac). Three doses of 5.12 × 10 PfSPZ of PfSPZ Challenge at 28-day intervals were well tolerated and safe， and prevented infection in 9 out of 9 (100%) volunteers who underwent controlled human malaria infection ten weeks after the last dose (group III). Protective efficacy was dependent on dose and regimen. Immunization with 3.2 × 10 (group I) or 1.28 × 10 (group II) PfSPZ protected 3 out of 9 (33%) or 6 out of 9 (67%) volunteers， respectively. Three doses of 5.12 × 10 PfSPZ at five-day intervals protected 5 out of 8 (63%) volunteers. The frequency of Pf-specific polyfunctional CD4 memory T cells was associated with protection. On a 7，455 peptide Pf proteome array， immune sera from at least 5 out of 9 group III vaccinees recognized each of 22 proteins. PfSPZ-CVac is a highly efficacious vaccine candidate; when we are able to optimize the immunization regimen (dose， interval between doses， and drug partner)， this vaccine could be used for combination mass drug administration and a mass vaccination program approach to eliminate malaria from geographically defined areas.